Business Wire

IDEMIA Awarded iBeta Certification for its Biometric Liveness Detection Solution

Share

IDEMIA, the global leader in Augmented Identity, has announced that its liveness detection technology has been awarded Level 1 and Level 2 certification by iBeta, an independent third-party tester, in accordance with the ISO/IEC 30107-3 standards.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200211005642/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

(Photo: Business Wire)

Testing was conducted by independent quality assurance provider, iBeta, and completed in December 2019. The testing method simulated the enrollment of a user in a biometric authentication system, where legitimate users consented to photos and videos of their likeness being used in attempts to spoof the system (Level 1 testing), and also the use of more sophisticated artefacts like silicone, latex, and plastic masks (Level 2 testing).

The testers were not able to gain access to the system using any of the presentation attacks, meaning that IDEMIA’s liveness detection technology achieved an attack presentation classification error rate (APCER) of 0%.

IDEMIA’s SmartBio® and WebBioServer® SDKs both leverage the liveness detection technology, which enables clients to offer multi-channel identity verification solutions via Android and iOS mobile apps, or through web browsers on either desktop or mobile devices.

Increasingly, banks, mobile operators, and other service providers are under pressure to offer their customers a remote, digital onboarding journey. The mass adoption of mobile devices with biometric sensors, combined with widespread broadband coverage worldwide, make this transformation possible.

However, remote onboarding presents an opportunity for fraudsters to open an account using a presentation attack, which is when spoofed biometric information is presented to a biometric sensor. Common presentation attacks include a fake image or video of a legitimate customer, fake silicon or gelatin masks, and fake fingerprints.

Presentation attack detection (PAD) is vitally important for service providers that want to secure their digital onboarding processes while reducing the impact of fraud. PAD also helps service providers comply with anti-money laundering (AML) and counter-terrorism financing (CTF) regulations, which may result in hefty penalties from regulators should their processes be deemed inadequate for accurately combatting fraud.

To date, IDEMIA is one of just two companies worldwide to have achieved Level 2 Liveness Detection certification.

“At IDEMIA, we pride ourselves in our ability to create cutting-edge biometric solutions capable of streamlining a user’s digital journey and combatting fraud,” said Muzaffar Khokhar, Executive Vice President, Digital Business Unit, IDEMIA. “This independent accreditation proves our expertise, and will enable us to provide a more complete portfolio of onboarding and anti-fraud solutions for our clients across the globe.”

IDEMIA’s liveness detection technology is available through the SmartBio® and WebBioServer® SDKs, and is part of the company’s innovative digital identity platform. The platform is a powerful solution for enterprises and service providers to identify, manage, and authenticate digital identities in a secure, trusted, and convenient way.

iBeta is the only NIST NVLAP accredited biometrics testing lab (NVLAP testing Lab Code 200962-0). iBeta developed a quality management system and biometrics test procedures that are independently audited by NVLAP (National Voluntary Laboratory Accreditation Program) in a comprehensive technical evaluation in accordance with the recognized International Standard ISO/IEC 17025:2017.

View the IDEMIA PAD Level 1 Confirmation Letter (PDF)
View the IDEMIA PAD Level 2 Confirmation Letter (PDF)

For more information on IDEMIA’s digital identity platform and other digital identity technology, visit https://www.idemia.com/digital-identity-enterprises

About IDEMIA

IDEMIA, the global leader in Augmented Identity, provides a trusted environment enabling citizens and consumers alike to perform their daily critical activities (such as pay, connect and travel), in the physical as well as digital space.

Securing our identity has become mission critical in the world we live in today. By standing for Augmented Identity, an identity that ensures privacy and trust and guarantees secure, authenticated and verifiable transactions, we reinvent the way we think, produce, use and protect one of our greatest assets – our identity – whether for individuals or for objects, whenever and wherever security matters. We provide Augmented Identity for international clients from Financial, Telecom, Identity, Public Security and IoT sectors.

With 13,000 employees around the world, IDEMIA serves clients in 180 countries.

For more information, visit www.idemia.com / Follow @IDEMIAGroup on Twitter

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Press
PR Agency: Havas Paris
Irina Pungaru
+33 6 13 02 34 76
idemia@havas.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

MRM Health Raises €55 Million Series B to Advance Best-in-Class Microbiome-Based Biotherapeutic Product Pipeline4.9.2025 08:00:00 EEST | Press release

MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced the successful closing of a €55 million (US$64 million) Series B financing round. The round was led by French pharmaceutical group Biocodex and included strong participation from German-based ATHOS, as well as new investor BNP Paribas Fortis Private Equity and existing investors SFPIM, Ackermans & van Haaren (AvH), OMX Europe Venture Fund (OMX), Qbic II and VIB. Validation of Leadership Position in Microbiome-Based Therapeutics Proceeds will enable MRM Health to complete a Phase 2b clinical trial for its lead program MH002 in patients suffering from mild-to-moderate ulcerative colitis. MH002 is currently the most advanced Live Biotherapeutic Product (LBP) based on rationally-designed combination of disease specific bacteria (microbial consortia), for the treatment of inflammatory bowel diseases (IBD), with positive clinical da

Abbove Unveils “Mia”: Opening a New Chapter in Digital Wealth Planning in Europe4.9.2025 07:00:00 EEST | Press release

Abbove, the European platform for collaborative and family-centered wealth planning, announces today the launch of Mia, its new artificial intelligence agent. Used by more than 1,100 advisors and deployed to over 37,000 families across Europe, Abbove takes a major step forward in its mission to reimagine the wealth advisory experience in the digital age. Designed to enhance the capabilities of wealth advisors, family officers, and financial experts, Mia acts as an intelligent co-pilot. It simplifies the reading and analysis of complex estate documents, automatically extracts key information, and assists users in the understanding, enrichment, and structuring of wealth data. “The launch of Mia opens an entirely new functional AI vertical on our platform, unlocking near-infinite possibilities for future development. It’s a key milestone that brings us closer to our ambition of becoming the leading pan-European wealth planning platform.” — Guillaume Desclée, Founder & CEO of Abbove Native

Biocytogen Enters into Agreement with Merck, KGaA, Darmstadt, Germany to Advance Antibody-Conjugated Lipid-Based Delivery Solutions4.9.2025 03:00:00 EEST | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies and Merck KGaA, Darmstadt, Germany, a leading science and technology company, have entered into an evaluation and option agreement to advance the development of antibody-conjugated lipid-based delivery solutions for nucleic acid payloads, such as antibody-conjugated lipid nanoparticle (LNP). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250903434045/en/ Under the terms of the agreement, Biocytogen will provide proprietary, fully human antibodies derived from its RenMice® platform for evaluation in Merck KGaA, Darmstadt, Germany’s antibody-conjugated LNP services. Merck KGaA, Darmstadt, Germany has been granted an exclusive option to acquire rights to selected antibody assets in return for fees and royalties on sales and su

OpZira, Inc. Launches to Advance Ophthalmic Diagnostics with Innovative Medical Device Portfolio3.9.2025 20:23:00 EEST | Press release

OpZira™, Inc., a forward-thinking ophthalmic medical device company founded on a legacy of research excellence, today announced its official formation. OpZira is dedicated to delivering innovative technologies that enhance the detection and monitoring of ocular disease, empowering clinicians with advanced diagnostic tools. OpZira’s creation follows Alcon’s acquisition of LumiThera (https://www.alcon.com/media-release/alcon-completes-acquisition-lumithera/) and its innovative Valeda® Light Delivery System, the first and only FDA-authorized treatment for dry age-related macular degeneration (AMD). As part of the transaction, LumiThera’s diagnostic product lines were spun off to LumiThera shareholders, leading to the establishment of OpZira, Inc. OpZira’s product portfolio includes: AdaptDx Pro® – A wearable dark adaptometer that leverages AI to ensure a consistent patient experience. Impaired dark adaptation speed, a key early indicator of rod-mediated dysfunction, is often among the fir

​ BTG Bioliquids and NanosTech Partner to Deliver End-to-End Advanced Biofuels Solution3.9.2025 19:19:00 EEST | Press release

BTG Bioliquids BV (BTL), a Netherlands-based leader in fast pyrolysis technology, and NanosTech Technology & Innovations Ltd. (NanosTech), a Canada-based catalyst development and manufacturing company, have signed a Memorandum of Understanding (MOU) to deliver a fully integrated solution to produce advanced, drop-in biofuels. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250903698730/en/ The partnership combines BTL’s proven fast pyrolysis technology, which converts sustainable biomass into bio-oil, with NanosTech’s proprietary Aquaprocessing (AQP) platform, which upgrades even the most challenging bio-oils into refinery-ready feedstocks to produce fuels such as sustainable aviation fuel (SAF), renewable diesel, and marine fuels. The two companies are now actively collaborating to determine the location in Canada and Europe for the new 500-barrel-per-day modular biorefinery system. This system can be deployed near the feeds

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye